ABVX:EPA
Abivax SA
77,15 €
arrow_downward
-0,64%(-0,50) 1 d.
6. nov., 17:36:06 GMT+1 · EUR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: ABVX…
Atvērt
74,45 €
Augsta
77,15 €
Zema
73,80 €
Tirgus kapitalizācija
6,84 mljrd.
Vid. apjoms
111,44 tūkst.
Apjoms
161,37 tūkst.
Augstākā 52 ned.
139,00 €
Zemākā 52 ned.
60,45 €
Peļņa uz vienu akciju
-5,20 €
Apgrozībā esošās akcijas
87,55 milj.
Darbinieku skaits
98
Atvērt
74,45 €
Augsta
77,15 €
Zema
73,80 €
Tirgus kapitalizācija
6,84 mljrd.
Vid. apjoms
111,44 tūkst.
Apjoms
161,37 tūkst.
Augstākā 52 ned.
139,00 €
Zemākā 52 ned.
60,45 €
Peļņa uz vienu akciju
-5,20 €
Apgrozībā esošās akcijas
87,55 milj.
Darbinieku skaits
98
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Finviz
·
pirms 23 minūtēm
PSQ Holdings Shrinks Losses And Cash Burn, But Slowing Growth, A Steep Q4 Target And NYSE Listing Risk Define The Setup
Reuters Connect
·
pirms 2 stundām
Traders work on the floor of the NYSE in New York
kalkine.ca
·
pirms 39 minūtēm
Can Small Caps Valued at USD 271.24 Million to USD 709.02 Million Back Up Their Records, Led by ACNB Corporation (NASDAQ:ACNB), California BanCorp (NASDAQ:BCAL), Avidbank Holdings (NASDAQ:AVBH), Acme United (NYSEAMERICAN:ACU) an
Barchart.com
·
pirms 1 stundas
Nasdaq Rout Gives Way to Unusual Options Activity and Bullish Bets on Nvidia, AT&T and Alphabet Stocks
Profils
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Par “Abivax SA”
ĢenerāldirektorsMarc de Garidel | Hartmut J. Ehrlich
Darbinieki98
Dibināšanas datums2013. gada 4. dec.
Galvenais birojs-
SektorsHealth Care
Nozare-
Tīmekļa vietneabivax.com